We understand that the microbiome has emerged as an important consideration in clinical science, and this includes extension into the important world of oncology. The role of the microbiome in cancer is not just limited to causation and cancer risk. We now known that the microbiome modifies immune responses to tumors. It influences the clinical course of cancer including the efficacy, bioavailability, and toxicity of chemotherapeutic and immunotherapeutic agents. The potential value of microbiome manipulation with live biotherapeutics or microbial transplantation has also become a realistic consideration. The link below is a prepublication summary of an article in press. Expect the PDF to be available shortly

See the abstract and article in the American Journal of Gastroenterology here.